Vancouver-based Forbes Medi-Tech has signed an international supply agreement with Australian firm Pan Pharmaceuticals for Reducol, a cholesterol-lowering phytosterol-based ingredient.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more


The initial supply agreement is for a minimum of three-years, and secures Sydney-based Pan Pharmaceuticals’ exclusive rights to supply Reducol in the form of a dietary supplement to the Australian market, and selected countries in Asia, the Middle East, Africa, as well as three countries in Europe.


“This agreement will give Forbes tremendous exposure in several key
international markets,” said Charles Butt, president and CEO of Forbes Medi-Tech: “Pan Pharmaceuticals has an intimate working knowledge of the cultures, regulatory systems and product preferences in these markets, which makes it an ideal partner for Forbes.”


Reducol is used in dietary supplements in the form of tablets capsules and soft-gel capsules.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Just Food Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Just Food Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now